These mutations can affect key regulators of vascular function, including endothelial nitric oxide synthase (eNOS) [19], vascular endothelial growth factor (VEGF) [20], and components of the renin-angiotensin system [21], contributing to the development and progression of PAD. The gene discussed is NOS3; the disease is peripheral arterial disease.